We obtained summary genome-wide association study (GWAS) statistics from Alterations in the Genome (PRACTICAL) consortium [35] . Summary statistics were also 1 0 9 obtained from analyses on 6,263 men with advanced prostate cancer (defined as Gleason 1 1 0 score ≥ 8, prostate-specific antigen >100 ng/mL, metastatic disease (M1), or death from Institutional Review Board approval from each country, in accordance with the Declaration of Helsinki. Genotype data were obtained by either direct genotyping using an Illumina 1 1 4 Custom Infinium array (OncoArray) consisting of approximately 530,000 SNPs [37] or by 1 1 5 9 imputation with reference to the 1000 Genomes Project Phase Three dataset [38] . All SNPs 1 1 6 with a poor imputation quality (r 2 <0.30), a minor allele frequency of <1%, a call rate of 1 1 7 <98%, or evidence of violation of Hardy-Weinberg equilibrium (P<10 -7 in controls or P<10 -1 1 8 12 in cases) were removed. Analyses were performed across individual studies in 1 1 9 PRACTICAL using logistic regression in models that were adjusted for the first seven principal components of ancestry (to control for population stratification) and study relevant covariates. Results were meta-analyzed across the PRACTICAL studies using an inverse- variance fixed-effects approach to give an overall effect-estimate. Calcium-associated SNP selection 1 2 5 SNPs to proxy for serum calcium were obtained from a GWAS meta-analysis of 1 2 6 39,400 individuals of European descent from 17 population-based cohorts [34] . Genetic instruments were constructed by obtaining SNPs shown to robustly (P<1x10 -7 ) and 1 2 8 independently to associate (r 2 <0.01) with serum calcium levels that were replicated (one-1 0 from previously published GWAS (MR-Base; www.mrbase.org) [40] . After applying a 1 4 0 Bonferroni correction to account for multiple "look ups" of phenotypic traits with all 7 SNPs performed; 859 to 1060 look-ups performed with corresponding corrected P-value thresholds: 5.8 x 10 -5 to 4.7 x 10 -5 across 7 SNPs), we identified two SNPs (rs780094, rs1550532) that 1 4 4 associated with multiple traits in MR-Base. rs780094 was robustly associated (P<4.8x10 -5 ) 1 4 5 with various measures of lipids, insulin, and anthropometric traits and rs1550532 was 1 4 6 robustly associated (P<4.8x10 -5 ) with inflammatory bowel disease; these traits have all been 1 4 7 hypothesized to influence prostate cancer risk [41] [42] [43] [44] . Additionally, rs1550532 was strongly 1 4 8 associated with levels of multiple "unknown metabolites" from untargeted GWAS of 1 4 9 metabolomic studies [45] . Given that these two SNPs could influence prostate cancer risk 1 5 0 through biological pathways independent of calcium (i.e. horizontal pleiotropy), we removed them from our genetic instrument. Consequently, our genetic instrument for calcium used 1 5 2 five SNPs that we assessed as being exclusively associated with serum calcium (rs17251221, Statistical analysis 1 5 6 We generated estimates of the proportion of variance in serum calcium for our genetic instrument (R 2 ) and F-statistics to examine the strength of our instruments and to test for weak instrument bias (a reduction in statistical power to reject the null hypothesis when an 1 5 9 instrument explains only a small proportion of variance in an exposure), using methods 1 6 0 previously described [46] . Power calculations were performed using previously reported methods [47] to determine whether we had sufficient sample size to identify effect sizes in our MR analyses that were of a similar magnitude to those reported in the observational 1 6 3 literature. 1 6 4 We first examined the effect of serum calcium on overall and advanced prostate 1 6 5 cancer for individual SNPs, using the Wald ratio to generate beta-coefficients, and the delta 1 6 6 method approximation of the standard error. SNPs were then combined into a multi-allelic 1 6 7 genetic instrument (to increase the variance explained in serum calcium) and the causal effect of this instrument on overall and advanced prostate cancer was examined using a maximum 1 6 9 likelihood-based approach [48] . For both individual-SNP and multi-allelic instrument
analyses, the effect of serum calcium on prostate cancer was scaled to represent a 0.5 mg/dL increase (~ 1 SD). I 2 statistics were calculated to determine the percentage of heterogeneity across SNPs in causal estimates due to variability beyond chance and Cochran's Q test was 1 7 3 used to test homogeneity across SNPs in causal estimates [49] . Maximum-likelihood 1 7 4 estimates were then generated using fixed-effects or random-effects models depending on 1 7 5 heterogeneity of causal effect estimates across SNPs in multi-allelic instruments. P-values 1 7 6 were generated using a t-distribution with N-1 degrees of freedom where N is the number of 1 7 7 SNPs utilized in the instrument. To examine the presence of directional pleiotropy (where the horizontally pleiotropic 1 7 9 effect across a genetic instrument do not average to zero) from unmeasured traits we Direct Effect) assumption is met (that no association exists between the strength of gene- exposure associations and the strength of bias due to horizontal pleiotropy) and that 1 8 8 measurement error in the genetic instrument is negligible ("No Measurement Error" or 1 8 9 NOME assumption) [52] , the slope generated from MR-Egger regression can provide an 1 9 0 estimate of the causal effect of calcium on prostate cancer that is adjusted for directional 1 9 1 pleiotropy and the intercept term can provide a formal statistical test for directional 1 9 2 pleiotropy. To test NOME, we generated weighted I 2 GX values for overall and advanced prostate cancer analyses to quantify the expected dilution of MR-Egger estimates due to 1 9 4 NOME violations [52] . The weighted median estimator (WME) approach provides an an instrument are ordered and weighted by the inverse of their variance. Unlike MR-Egger which can provide an unbiased causal effect even when all IVs are invalid, WME requires that at least 50% of the information in a multi-allelic instrument is coming from SNPs that are 1 9 9 valid IVs in order to provide an unbiased estimate of a causal effect in an MR analysis. However, the WME has two advantages over MR-Egger in that it provides improved precision as compared to the latter and does not rely on the InSIDE assumption. We also performed a leave-one-out permutation analysis to examine whether any of 2 0 3 our results were driven by any individual SNP from our multi-allelic instrument. All statistical analyses were performed using R version 3.3.1. Our genetic instrument explained 0.71% of variance in serum calcium levels. The to suffer from weak instrument bias [53] . Power calculations suggested that we would have Estimates of causal effects of individual calcium SNPs per 0.5 mg/dL increase in serum calcium on overall and advanced prostate cancer per are presented in Table 1 . Individually, there was little evidence that any of the 5 SNPs were causally associated with overall or advanced prostate cancer. Overall prostate cancer 2 2 2 In an MR analysis combining the five serum calcium-related SNPs into a multi-allelic (Table 2) . Sensitivity analyses to examine directional pleiotropy were consistent with a null effect of serum calcium on advanced prostate cancer. Calculation of the I 2 GX statistic suggested little attenuation of our MR-Egger estimates 2 3 6 due to measurement error for both overall prostate cancer (I 2 GX =0.89) and advanced prostate 2 3 7 cancer (I 2 GX =0.91), so adjustment of MR-Egger estimates to account for mild dilution bias 2 3 8 was not performed [52] . Leave-one-out permutation analyses for overall and advanced prostate cancer did not find evidence that the effect estimate based on the multi-allelic Our Mendelian randomization analysis does not support the hypothesis that serum were in the opposite direction (though imprecisely estimated) to findings from some 2 4 7 observational studies. Our findings are not consistent with some laboratory studies which have reported a 2 4 9 role of calcium in promoting loss of differentiation and increased proliferation of prostate 2 5 0 cancer cells [54, 55] . Further, our results are not consistent with a meta-analysis of prospective observational studies that reported dose-response relationships of dietary calcium intake (per 400 mg/day) with risk of prostate cancer (RR 1.05, 95% CI: 1.02-1.09, N=15
that we found for a potential protective effect of serum calcium on overall prostate cancer is
consistent with a meta-analysis of four randomized controlled trials that reported that daily Strengths of our analysis include the use of a Mendelian randomization approach to 2 7 5 appraise the relationship of serum calcium with prostate cancer risk which should help to 2 7 6 minimize or avoid confounding through lifestyle or environmental factors that may have biased findings from previous observational analyses. Further, given the time required for nutritional biomarkers to influence carcinogenesis [57] and the considerable latency period of prostate cancer [58] , the use of germline genetic variation as an instrument should allow for 2 8 0 sufficient time to confer an effect on prostate cancer. This is because MR will estimate the suffer from substantial (albeit, likely non-differential) measurement error: measurement error 2 8 4 in genetic studies is often low as modern genotyping technologies provide relatively precise 2 8 5 measurement of genetic variants [59] . The use of a two-sample MR approach allowed us to 2 8 6 utilize summary effect estimates from two large GWAS and thus increase statistical power in 2 8 7 our analyses. Additionally, though the F-statistic generated for our instrument suggested that present would be expected to bias associations toward the null, providing a conservative bias will tend to bias effect estimates toward the confounded observational study estimate [36]. Lastly, by obtaining summary effect estimates for both exposure and outcome datasets 2 9 3 from GWAS that were restricted to individuals of European descent and adjusted for 2 9 4 principal components of ancestry, we reduced (though did not eliminate) the possibility of confounding through population stratification in our MR analyses (though this may limit 2 9 6 generalizability of our findings to other ethnicities). There are limitations to our analysis. First, given the composite characterization of 2 9 8 advanced prostate cancer in the summary GWAS data that we obtained (Gleason ≥ 8, prostate-specific antigen >100 ng/mL, metastatic disease (M1), or death from prostate 3 0 0 cancer), it is difficult to directly compare our findings with those from prospective studies that examined associations between calcium and fatal prostate cancer. Second, though our variants that influence serum calcium (increasing instrument strength further by explaining a our analysis was that we were unable to examine possible non-linear effects of serum calcium 3 0 9
on prostate cancer using summarized genetic data, which have been proposed previously [8] . 3 1 0
Given that our findings raise the possibility that serum calcium may be protective
against prostate cancer, there is a need to follow-up these results in large and independent datasets. Further identification of additional independent genetic variants robustly associated with serum calcium will help to improve precision of future analyses. In conclusion, our Mendelian randomization analysis does not support the hypothesis that serum calcium increases the risk of overall or advanced prostate cancer. Interval. EA reflects the allele that increases serum calcium levels. OR (95% CI) represents the exponential increase in odds for each 0.5 mg/dL increase in serum calcium 2 0 
